Trial Profile
A Phase II Evaluation of Paclitaxel (Taxol, NSC 673089), Carboplatin (Paraplatin, NSC 241240), and BSI-201 (NSC 746045, IND 71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2012
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Iniparib (Primary) ; Paclitaxel (Primary)
- Indications Uterine cancer
- Focus Therapeutic Use
- 23 May 2012 Actual patient number is 22 as reported by ClinicalTrials.gov.
- 23 May 2012 Actual patient number is 22 as reported by ClinicalTrials.gov.
- 23 May 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.